IGC Pharma financials
$0.2675−2.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 | FY19 Mar 31 | FY18 Mar 31 | FY17 Mar 31 | FY16 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.3M | $911.0K | $397.0K | $898.0K | $4.1M | $5.1M | $2.2M | $580.4K | $6.4M |
| Gross profit | $619.0K | $733.0K | $442.0K | $194.0K | $113.0K | $115.0K | $132.0K | $82.0K | $218.2K | $843.3K |
| Gross margin | 48.7% | 54.5% | 48.5% | 48.9% | 12.6% | 2.8% | 2.6% | 3.7% | 37.6% | 13.2% |
| Operating income | -$7.4M | -$9.8M | -$11.6M | -$15.4M | -$8.7M | -$6.9M | -$4.6M | -$1.8M | -$2.1M | -$2.6M |
| Net income | -$7.1M | -$13.0M | -$11.5M | -$15.0M | -$8.8M | -$7.3M | -$4.1M | -$1.8M | -$1.9M | -$2.8M |
| Net margin | −560.3% | −966.5% | −1263.0% | −3782.4% | −981.2% | −179.6% | −80.1% | −81.4% | −321.7% | −44.1% |
| Diluted EPS | $-0.09 | $-0.22 | $-0.22 | $-0.30 | $-0.21 | $-0.19 | $-0.13 | $-0.06 | $-0.07 | $-0.17 |
| EBITDA | -$6.9M | -$9.2M | -$10.9M | -$14.8M | -$8.2M | -$6.7M | -$4.6M | -$1.8M | -$1.7M | -$1.9M |
| Operating cash flow | -$4.8M | -$5.2M | -$7.0M | -$7.5M | -$10.8M | -$8.7M | -$3.3M | -$1.9M | -$1.5M | -$157.7K |
| Free cash flow | -$4.9M | -$5.3M | -$7.4M | -$7.7M | -$12.3M | -$13.1M | -$3.3M | -$2.1M | -$1.7M | -$279.9K |
| Diluted shares | 76.5M | 58.8M | 52.6M | 50.0M | 42.0M | 39.5M | 35.4M | 27.9M | 25.7M | 16.4M |
Balance sheet
| Period end | Dec 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $900.0K | $1.2M | $3.2M | $10.5M | $14.5M | $7.3M |
| Short-term investments | $38.0K | $0.00 | $154.0K | $0.00 | $80.0K | $5.1M |
| Total debt | $311.0K | $137.0K | $141.0K | $144.0K | $580.0K | $50.0K |
| Total assets | $9.7M | $9.9M | $17.2M | $26.8M | $35.9M | $29.0M |
| Total liabilities | $2.3M | $2.6M | $2.3M | $2.9M | $3.1M | $2.4M |
| Shareholders' equity | $7.4M | $7.3M | $14.9M | $23.9M | $32.8M | $26.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology